Modules

Share

Program Content

Activities

  • CLL Treatment Evolution
    Evolving CLL Treatment Recommendations
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 06, 2022

    Expires: October 05, 2023

  • 1L Therapy
    Individualizing Frontline Therapy for Patients With Chronic Lymphocytic Leukemia: Putting Evidence Into Practice
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 19, 2022

    Expires: April 18, 2023

  • Patient CLL Concerns
    Addressing Patient Knowledge Gaps, Concerns, and Misperceptions About CLL
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 17, 2022

    Expires: August 16, 2023

  • MRD in CLL
    Assessing Measurable Residual Disease in Chronic Lymphocytic Leukemia
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 30, 2022

    Expires: August 29, 2023

  • AEs With BCL-2i/PI3Ki
    Multidisciplinary Perspectives on Managing Adverse Events With BCL-2 and PI3K Inhibitors in CLL
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 19, 2022

    Expires: May 18, 2023

  • AEs With BTKis
    Multidisciplinary Perspectives on CLL-Related Symptoms and Managing Adverse Events With BTK Inhibitors
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 31, 2022

    Expires: May 30, 2023

Provided by

ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Eli Lilly

Janssen Biotech

Pharmacyclics an AbbVie Company

TG Therapeutics

Partners

CLL Society

ProCE Banner